A5082627101- Hemoglobinopathies and Related Disorders
- Iron Metabolism and Disorders
- Blood groups and transfusion
- Prenatal Screening and Diagnostics
- Tuberculosis Research and Epidemiology
- Pharmacological Effects and Toxicity Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Erythrocyte Function and Pathophysiology
- Autopsy Techniques and Outcomes
- Neonatal Health and Biochemistry
- Pregnancy and preeclampsia studies
- Acute Ischemic Stroke Management
- Parvovirus B19 Infection Studies
- Child Nutrition and Water Access
- Genomics and Rare Diseases
- Diagnosis and treatment of tuberculosis
- HIV/AIDS Impact and Responses
- Malaria Research and Control
- Folate and B Vitamins Research
- Erythropoietin and Anemia Treatment
- Immunodeficiency and Autoimmune Disorders
- Blood disorders and treatments
- Mycobacterium research and diagnosis
- Bone and Joint Diseases
- Metabolomics and Mass Spectrometry Studies
University of Padua
2016-2025
Azienda Ospedaliera di Padova
2015-2024
Regione del Veneto
2016-2023
Aid Health and Development Onlus
2015-2022
Associazione Italiana Vulvodinia Onlus
2022
Woman's Hospital
2021
Mater Hospital
2004
Institut Gustave Roussy
1999-2004
Olgahospital
1999-2004
Birmingham Children's Hospital
1999
Sickle cell anemia is an inherited blood disorder that characterized by painful vaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle anemia, suggests a role antiplatelet agents modifying disease events.Children adolescents 2 through 17 years of age with were randomly assigned to receive oral prasugrel or placebo 9 24 months. The primary end point was the rate crisis, composite crisis acute...
Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European care systems. Newborn screening (NBS) for SCD enables early initiation of preventive measures has contributed a reduction in childhood mortality from SCD. Policies methodologies NBS vary different countries, this might have consequences the quality clinical outcomes across Europe. A two-day Pan-European consensus conference was held Berlin April 2017 order appraise current status...
Abstract Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso‐occlusive crises (VOCs). Data on the global SCD impact quality of life (QoL) from patient viewpoint are limited. The international Cell World Assessment Survey (SWAY) aimed to provide insights into patient‐reported QoL. This cross‐sectional survey patients enrolled healthcare professionals advocacy groups assessed daily life, education work, symptoms, treatment goals, management. Opinions...
Final results are presented from two consecutive European studies for patients with metastatic rhabdomyosarcoma (RMS) to identify prognostic variables and determine the value of high-dose chemotherapy (HDCT) in complete remission.A total 174 aged 3 months 18 years participated. From 1989 1991, received four cycles intensive multiagent chemotherapy. 1991 1995, achieving remission consolidation HDCT. All local therapy (surgery, radiation therapy) according response.At a median follow-up 8...
Several controlled studies have evidenced good efficacy and short-term mid-term safety profiles for hydroxyurea (HU), which has become the cornerstone prevention of sickle-cell disease (SCD)-related vaso-occlusive crises. However, there are few large-scale reports on its long-term use certain caregivers patients concerns about safety. Following licensing HU in Europe children adults with severe forms SCD, ESCORT-HU was designed as a Phase IV observational cohort study. It included 1906...
Background: Sickle cell disease (SCD) has a high prevalence and social impact worldwide, with mortality within the first three years of life. A been reported in sub-Saharan Africa, Mediterranean, Middle East, India. With global migration, is also increasing other geographic regions, but there are no definitive data on SCD. Aims: To perform systematic literature review (SLR) available evidence epidemiological burden (prevalence, birth mortality/life expectancy) Methods: comprehensive search...
PURPOSE: The European Collaborative MMT4-91 trial was conducted as a prospective nonrandomized study to evaluate the potential benefit of high-dose melphalan consolidation first complete remission in children with stage IV rhabdomyosarcoma. PATIENTS AND METHODS: Fifty-two patients after six courses chemotherapy received “megatherapy”: 42 alone, whereas 10 combination etoposide, carboplatin/etoposide, or thiotepa/busulfan and etoposide. outcome this group compared that observed 44 who were...
The Guinea-Bissau family of strains is a unique group the Mycobacterium tuberculosis complex that, although genotypically closely related, phenotypically demonstrates considerable heterogeneity. We have investigated 414 M. collected in between 1989 and 2008 order to further characterize strains. To determine strain lineages present study sample, binary outcomes spoligotyping were compared with spoligotypes existing international database SITVIT2. major circulating clades ranked following...
BackgroundThrombotic complications in Sickle Cell Disease (SCD) arise since infancy, but the role of coagulation system children has been poorly explored. To determine its development clinical childhood we measured and endothelial parameters with SCD at steady state. MethodsMarkers thrombin generation, fibrin dissolution activation were evaluated 38 SS-Sβ°, 6 SC disease 50 age blood group matched controls. Coagulation variables correlated markers hemolysis inflammation, presence cerebral...
The number of patients with sickle cell disease (SCD) has increased in Italy the past decade due to immigration. In spite established efficacy hydroxyurea (HU) childhood, population-based data regarding its prescription and effectiveness come mainly from studies performed adults or outside Europe.The Hydroxyurea SCD: A Large Nation-wide Cohort Study was a retrospective cohort study adult pediatric SCD attending 32 centers. Pediatric are analyzed separately.Out 504 children followed 11...
Background Moyamoya is a rare progressive cerebral arteriopathy, occurring as an isolated phenomenon (moyamoya disease, MMD) or associated with other conditions syndrome, MMS), responsible for 6–10% of all childhood strokes and transient ischemic attacks (TIAs). Methods We conducted retrospective multicenter study on pediatric-onset MMD/MMS in Italy order to characterize disease presentation, course, management, neuroradiology, outcome European country. Results A total 65 patients (34/65...
Universal neonatal screening is performed in the United States, England, Netherlands, and several cities Belgium, with selective targeted on "high-risk" population France (globally, one quarter of all babies born are screened). Newborns diagnosed a major sickle cell syndrome (SCD) should be referred to designated pediatric centre, parents informed that their child has SCD; this may centre by an expert physician or community experienced nurse counsellor. The organize care baby.
Abstract Background Comprehensive care and advances in clinical investigations have reduced morbidity mortality sickle cell disease (SCD), but only a minority of children with SCD has access to comprehensive care. In Europe the majority patients are immigrants who present barriers accessing health system; therefore, new evidence‐based models needed ensure that all receive high‐quality care, overcoming patient‐ system‐related barriers. We wanted verify if addressing specific needs immigrant...
Sickle cell disease (SCD) is the most frequent hemoglobinopathy worldwide but remains a rare blood disorder in western countries. Recommendations for standard of care have been produced United States, Kingdom and France, where this relatively because earlier immigration from Africa. These recommendations changed clinical course SCD can be difficult to apply other contexts. The Italian Association Pediatric Hematology Oncology (AIEOP) decided develop common national response rising number...